Background: Prognosis is poor for patients with critical limb ischemia (CLI), and the most frequent cause of death is cardiovascular disease. Low grip strength is a risk factor for cardiovascular events, and sarcopenia may be associated as well. Thus, we hypothesized that sarcopenia is a risk factor for cardiovascular events experienced by patients with CLI. If this is true and appropriate therapy becomes available, the prognosis of patients with CLI will improve with appropriate risk management strategies to prevent cardiovascular events. Therefore, the aim of this study was to verify this hypothesis.
The prognosis of patients with critical limb ischemia (CLI) is very poor; they frequently experience cardiovascular events, and approximately 50% die within 5 years of diagnosis. [1] [2] [3] The guidelines for peripheral artery disease recommend risk management to prevent cardiovascular events. [4] [5] [6] Therefore, it is important to investigate the causes of cardiovascular events and to develop a strategy for preventing cardiovascular events experienced by patients with CLI. We previously reported that sarcopenia is a risk factor for worse overall survival of patients with CLI, 7 although the cause is unknown. Leong et al 8 reported that low grip strength is a risk factor for cardiovascular events and suggested that sarcopenia is a risk factor as well. Thus, we hypothesized that sarcopenia is a risk factor for cardiovascular events for patients with CLI. If this is true, and if appropriate therapy is available for such patients, their prognosis will be improved through appropriate preventive risk management. Although sarcopenia is treated with resistance training and nutritional therapy, [9] [10] [11] there are no reports to our knowledge that address risk management to prevent cardiovascular events in patients with sarcopenia. Therefore, the aim of this study was to investigate the relationship between sarcopenia and cardiovascular events to facilitate the development of appropriate risk management strategies for patients with CLI and sarcopenia.
METHODS
Study approval. The Institutional Review Board of Kyushu University approved this study . Informed consent was not waived because of retrospective nature. Instead of informed consent, we disclose all information about the study protocol to patients with The editors and reviewers of this article have no relevant financial relationships to disclose per the JVS policy that requires reviewers to decline review of any manuscript for which they may have a conflict of interest.
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Copyright Patients. We conducted a retrospective study of patients with CLI who were diagnosed with Fontaine stage III or IV peripheral artery disease who underwent revascularization at the Department of Surgery and Science, Kyushu University Hospital, Fukuoka, Japan, from January 2002 to December 2012. These patients underwent imaging studies that included preoperative computed tomography (CT), angiography, and magnetic resonance angiography.
Clinical characteristics were retrieved from patients' medical records that included age, sex, skeletal muscle area (SMA), skeletal muscle index (SMI; defined as SMA/height 2 ), body mass index (BMI), serum albumin levels, Fontaine categories, nonambulatory status, smokers with a Brinkman index >400, hypertension, diabetes mellitus, dyslipidemia, ischemic heart diseases, cerebrovascular disease, hemodialysis, treatment procedures, <2-year death, cause of death, oral medical therapies, and cardiovascular event-free survival.
Medications included aspirin, ticlopidine/clopidogrel, cilostazol, warfarin, insulin, and statins, which were administered within 30 days after surgery and were used daily thereafter. Single antiplatelet therapy (SAPT) was defined as the use of one antiplatelet drug, and dual antiplatelet therapy (DAPT) was defined as the use of two antiplatelet drugs regardless of type. We evaluated the association between cardiovascular events and drugs administered to patients with or without sarcopenia.
Diagnosis of sarcopenia.
We assessed preoperative transverse CT images of the third lumbar vertebra in the lower border to diagnose sarcopenia. Skeletal muscle was identified and quantified as previously described. 7, 12, 13 The presence of sarcopenia was defined as SMA <114.0 cm 2 for men and <89.8 cm 2 for women.
7
Definition of cardiovascular events. Cardiovascular diseases included ischemic heart disease, acute heart failure, cerebrovascular disease, and abdominal organ and limb ischemia. Cardiovascular events were defined as hospitalization because of cardiovascular disease.
Follow-up strategy. All patients were examined in the outpatient clinic 1 month after revascularization, with reassessment every 3 months if there were no problems.
Statistical analysis. The associations of continuous and categorical variables with clinically relevant outcome variables were assessed using the Student t-test and Fisher exact test, respectively. The associations among three variables were assessed using one-way factorial analysis of variance. The overall survival curves were analyzed using the Kaplan-Meier method and compared with the results of the log-rank test. Univariate analysis of clinicopathologic factors and cardiovascular event-free survival was performed using the log-rank test. Multivariate analyses of clinicopathologic factors and cardiovascular event-free survival were performed using the Cox proportional hazards model. All analyses were performed using JMP software version 9.0 (SAS Institute, Cary, NC). P < .05 was considered statistically significant according to the American Medical Association guidelines.
RESULTS
Characteristics of patients with or without sarcopenia. We included 196 patients with CLI in the present study. Preoperative CT was administered to 114 (58.2%) patients. We excluded 82 patients who were unable to undergo CT scans because of costs and allergy to the contrast media. None of the patients who underwent CT scans were excluded from the current study. Of the 114 patients who underwent CT scans, 53 (46.5%) had sarcopenia and 61 (53.5%) did not. The clinicopathologic characteristics of patients are summarized in Table I . There were significant differences between patients with and without sarcopenia as a function of age, SMA, BMI, nonambulatory status, hemodialysis, oral cilostazol therapy, and insulin use (all P < .05). No patient received triple antiplatelet therapy. Table II shows postoperative deaths and the causes. During follow-up, cardiovascular disease caused the deaths of 4 and 15 patients without and with sarcopenia (P < .01), respectively, and in particular, ischemic heart disease caused the deaths of 0 and 5 patients without or with sarcopenia (P < .05), respectively.
Cardiovascular event-free survival of patients with or without sarcopenia. Fig 1 shows the cardiovascular disease-free survival curves of patients with or without sarcopenia. There was a significant difference between patients with and without sarcopenia (P < .01). Three-year cardiovascular event-free survival rates were 43.1% and 91.2% for patients with and without sarcopenia, respectively. To exclude the effects of dialysis, we assessed the significance of sarcopenia in nondialysis patients. Sarcopenia was a risk factor as well for cardiovascular events in nondialysis patients (HR, 4.76; 95% CI, 2.18-11.0; P < .01). Multivariate analysis identified the independent variables associated with cardiovascular event-free survival as follows: sarcopenia (HR, 3.07; 95% CI, 1.56-6.29; P < .01); hemodialysis (HR, 3.13; 95% CI, 1.59-6.08; P < .01); SAPT (HR, 0.46; 95% CI, 0.24-0.82; P < .01); and statin use (HR, 0.38; 95% CI, 0.16-0.78; P < .01).
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Influence of orally administered drugs on cardiovascular event-free survival of patients with or without sarcopenia. Table IV presents the results of univariate analysis of the association of orally administered drugs with cardiovascular event-free survival. SAPT reduced (HR, 0.32; 95% CI, 0.12-0.71; P < .01) and DAPT significantly increased the risk for cardiovascular events in patients with sarcopenia (HR, 2.27; 95% CI, 1.06-4.76; P < .05; Table IV ). Patients with sarcopenia who received SAPT experienced significantly longer cardiovascular eventfree survival (P < .05) compared with the others (Fig 2) . Three-year cardiovascular event-free survival rates were 75.3%, 21.1%, and 29.5% for patients with sarcopenia who received SAPT, DAPT, or no antiplatelet therapy. There were no differences among the combinations of DAPT. There were two deaths and no deaths caused by bleeding among patients who received DAPT and SAPT, respectively. The difference in cardiovascular event-free survival between patients who received DAPT and patients who received no antiplatelet therapy was not significantly different.
DISCUSSION
This study revealed that sarcopenia is a risk factor for worse cardiovascular event-free survival, and SAPT and statins reduced the risk of cardiovascular events in patients with CLI. Furthermore, SAPT reduced the risk of cardiovascular events of patients with sarcopenia. Our previous study evaluated sarcopenia as a risk factor for overall survival; however, significant data were not available to determine the causes of death. 7 Therefore, treatment and risk management of patients with sarcopenia are unknown. In the current study, we clarified the specific causes of death of patients with sarcopenia and found that SAPT was appropriate for patients with sarcopenia. We believe that the current study represents the first step to prevention of cardiovascular events in patients with CLI and sarcopenia. Patients with sarcopenia experienced an increased frequency of cardiovascular events and death caused by cardiovascular disease. In contrast, patients without sarcopenia experienced neither (Table II; Fig 1) . These findings indicate that risk management to prevent cardiovascular events will improve the outcomes of patients with sarcopenia. Therefore, specific risk management strategies are required to prevent cardiovascular events in patients with CLI. Although patients without sarcopenia had significantly fewer cardiovascular events compared with patients with sarcopenia, the patients without sarcopenia will likely benefit as well from management designed to prevent cardiovascular events. 14, 15 For example, most patients with CLI have systemic arteriosclerosis despite the presence of sarcopenia.
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Sarcopenia, which occurs in patients with different diseases, is a risk factor for poor prognosis, although a relationship between sarcopenia and causes of death in the studies cited is unclear. 7, 13, [16] [17] [18] [19] Leong et al 8 reported that low grip strength is a risk factor for cardiovascular events and suggested that sarcopenia is a risk factor as well. Moreover, the current study showed that sarcopenia is a risk factor for cardiovascular events (Fig 1 and Table III) . The mechanisms through which sarcopenia influences cardiovascular events are unclear, but we hypothesized that the exercise tolerance of patients with sarcopenia decreased and led to overloading of heart functions. Kaplan-Meier survival curves of patients with or without sarcopenia. There was a significant difference between patients with and without sarcopenia (P < .01, log-rank test). Standard error does not exceed 10%. Resistance training and nutritional therapies used to treat sarcopenia [9] [10] [11] are not used to treat patients with cardiovascular disease, and whether sarcopenia is a cause or a consequence of cardiovascular diseases is unknown. If sarcopenia causes cardiovascular disease, resistance training and nutritional therapy will prevent cardiovascular events. The American Heart Association recommends resistance training to prevent cardiovascular events. 20, 21 Therefore, sarcopenia may cause cardiovascular events and therefore serve as a therapeutic target to prevent cardiovascular events. We showed here that cardiovascular event-free survival of patients with sarcopenia is lower compared with that of patients without sarcopenia. Antiplatelet therapies and statins are recommended to prevent cardiovascular events, [4] [5] [6] 22 consistent with the findings of the present study (Table III) . In particular, SAPT was beneficial but DAPT was harmful (Table IV; Fig 2) to patients with sarcopenia, suggesting that SAPT might be appropriate for patients with sarcopenia, although one study found that DAPT reduced major adverse cardiovascular events in patients with symptomatic peripheral arterial disease. 23 We reasoned that SAPT might be sufficient for patients who did not undergo percutaneous coronary intervention (PCI) because DAPT is used for patients who undergo PCI to prevent thrombosis from occurring in a stent. 24 The administration of DAPT should therefore be minimized, except after PCI. [25] [26] [27] In the current study, SAPT was beneficial, although there were no detectable differences in the use of aspirin, ticlopidine/clopidogrel, and cilostazol. Therefore, they were administered according to comorbidities, such as cerebral ischemia, ischemic heart disease, and intermittent claudication.
20,21
DAPT increases the risk of bleeding 26, 27 ; however, there were relatively few deaths caused by bleeding in the current study. The mechanism responsible for this association is unknown and must be identified by future studies. Furthermore, we did not detect significant differences between pairs of drugs used for DAPT, indicating that any form of DAPT may not benefit patients with sarcopenia.
Although patients included in our study had low BMIs, this might reflect the standard for Japanese people. Sarcopenic obesity with both low SMA and high BMI may represent a risk factor for cardiovascular events as mentioned in our previous report. 7 Therefore, it is difficult to explain loss of skeletal muscle associated with malnutrition and BMI, and it is therefore important to measure the area of skeletal muscle. The percentage of patients with dyslipidemia was low in the current study. Furthermore, the consumption of low-fat diets in Japan and the few obese people studied here reflect this result. Treatments for nonambulatory patients may be reflected by the Japanese standard. In general, it is difficult for many Japanese people, including patients and families, to accept amputation. Moreover, nonambulatory patients in the current study included those who were unable to walk but could stand. If patients can stand using their limbs, it is easy for patients and caregivers to use a wheelchair and a toilet seat. Limb salvage is believed to improve a patient's quality of life in Japan. We considered the diagnosis of sarcopenia with SMA and SMI, although there is not a defined cutoff value for SMI for Japanese people. Furthermore, we analyzed the trend-line of SMA and SMI and determined that R 2 ¼ .85 (Fig 3) , suggesting that SMA and SMI are closely related and that SMA and SMI could be selected to diagnose sarcopenia. Therefore, we used SMA to diagnose sarcopenia in Japanese patients because it has a defined cutoff value. 
